Relevance of EGFR gene mutation with pathological features and prognosis in patients with non–small–cell lung carcinoma

Wang, Chengde; Wang, Xinrong; Wang, Chaoyang; Tang, Yijun; Hao, Ming-Wen

doi:10.1016/s1995-7645(14)60326-6

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study revealed a significant relationship between blood type and EGFR mutation; however, the investigators did not mention the specific blood type, and analyses were secondary. 22 Also, EGFR mutation was not associated with smoking history in this study. The current case-control study included only lung adenocarcinoma patients with the main objective to evaluate blood type as a predictive factor for EGFR mutation status.…”

Section: Discussionmentioning

confidence: 43%

See 1 more Smart Citation

Association Between Blood Type and Epidermal Growth Factor Receptor Mutation Positivity in Lung Adenocarcinoma Patients

Gürbüz¹,

Akkuş²,

Karaalioğlu³

et al. 2021

J Oncol Sci

View full text Add to dashboard Cite

Specific ABO blood group and Rh antigens are found to be associated with several malignancies and lung cancer. However, the relationship between blood type and Epidermal Growth Factor Receptor (EGFR) mutation in lung cancer remains poorly investigated. Material and Methods: In this retrospective case-control study, 105 EGFR mutation-positive and 169 EGFR mutation-negative lung adenocarcinoma patients were included. Baseline characteristics of the patients were determined. Odds ratios were calculated for the relationship of EGFR mutation positivity according to the ABO and Rh blood type. Overall survival difference according to the blood types was analyzed in metastatic patients that were diagnosed in the EGFR-mutant group. Results: There was no statistically significant increase observed in the relationship of EGFR mutation positivity for any of ABO and Rh types (OR and p-value, respectively; A

show abstract

Section: Discussionmentioning

confidence: 43%

“…[12][13][14][15][16][17][18][19][20] However, to our knowledge, only two studies have investigated the relationship between blood type and EGFR mutation in lung cancer, and thus it remains poorly investigated. 21,22 The study aims to evaluate the relationship between blood type and EGFR mutation positivity in lung adenocarcinoma patients.…”

mentioning

confidence: 99%

Association Between Blood Type and Epidermal Growth Factor Receptor Mutation Positivity in Lung Adenocarcinoma Patients

Gürbüz¹,

Akkuş²,

Karaalioğlu³

et al. 2021

J Oncol Sci

View full text Add to dashboard Cite

show abstract

EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion

Zhang

Song

et al. 2020

Molecular and Cellular Probes

View full text Add to dashboard Cite

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC

Chen,

Zheng,

et al. 2024

BMJ Open Resp Res

View full text Add to dashboard Cite

ObjectivesThis study aims to explore how pre-existing conditions such as blood types, family history of cancer and comorbid diseases correlate with the genetic and programmed death-ligand 1 (PD-L1) expression that contributes to the heterogeneous biological behaviours of non-small cell lung cancer (NSCLC).Materials and methodsA cohort of 5507 NSCLC patients who underwent surgical resection between January 2014 and July 2018 was studied. Targeted next-generation sequencing was used to detect mutations in nine pivotal cancer-related genes, and immunohistochemical staining was applied to assess PD-L1 expression. Logistic regression analysis was employed to identify significant correlations.ResultsAll patients underwent NGS, with 1839 were also evaluated for PD-L1 expression. Several significant findings were found: ROS1 mutations were closely associated with a family history of lung cancer (OR 7.499, 95% CI 1.094 to 30.940, p=0.013). Epidermal growth factor receptor (EGFR) L858R mutations were common among patients with a family history of non-lung cancers and those with hypertension (OR 2.089, 95% CI 1.029 to 4.135, p=0.037 and OR 1.252, 95% CI 1.001 to 1.562, p=0.048, respectively). Pre-existing conditions such as diabetes and hepatitis B surface antigen positivity (OR 1.468, 95% CI 1.042 to 2.047, p=0.026 and OR 1.373, 95% CI 1.012 to 1.847, p=0.038, respectively) were correlated with EGFR exon 19 deletions. RhD negativity showed potential ties to BRAF mutations (OR 0.010, 95% CI 0.001 to 0.252, p=0.001). A history of tuberculosis linked to increased PD-L1 expression in immune cells (OR 3.597, 95% CI 1.295 to 14.957, p=0.034).ConclusionThis large-scale, cross-sectional study reveals a complex interplay between genetic mutations, immunological features and pre-existing conditions in NSCLC patients, offering insights that could inform personalised treatment strategies.

show abstract

Relevance of EGFR gene mutation with pathological features and prognosis in patients with non–small–cell lung carcinoma

Abstract: EGFR gene mutation has significant relevance with pathological features, the prognosis of EGFR-mutant-patients is better than that of EGFR- wide type-patients.

Cited by 4 publications

References 13 publications

Association Between Blood Type and Epidermal Growth Factor Receptor Mutation Positivity in Lung Adenocarcinoma Patients

Association Between Blood Type and Epidermal Growth Factor Receptor Mutation Positivity in Lung Adenocarcinoma Patients

EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC

Contact Info

Product

Resources

About